eBulletin Newsletter

NCCN Templates Updated for Small Bowel Adenocarcinoma, Non-Small Cell Lung Cancer, and More

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for Small Bowel Adenocarcinoma to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Small Bowel Adenocarcinoma v1.2021.

• The Title has been updated on the following NCCN Templates^® to be consistent with our standard naming conventions:
  • SBA26: Albumin-bound PACLItaxel/Gemcitabine
  • SBA27: DOCEtaxel/Gemcitabine
  • SBA28: PACLItaxel/Gemcitabine
• Changes to the Indication section have been made on the following templates:
  • SBA2: Roswell Park Fluorouracil/Leucovorin
  • SBA3: Simplified Biweekly Infusional Fluorouracil/Leucovorin
  • SBA4: Capecitabine
  • SBA5: Capecitabine with Concurrent Radiation
  • SBA6: Continuous Infusion Fluorouracil with Concurrent Radiation
  • SBA7: CapeOX (Capecitabine/OXALIplatin)
  • SBA8: mFOLFOX7 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin)
  • SBA9: mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) + Bevacizumab
  • SBA10: CapeOX (Capecitabine/OXALIplatin) + Bevacizumab
  • SBA12: FOLFOXIRI (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin/Irinotecan)
  • SBA13: FOLFOXIRI (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin/Irinotecan) + Bevacizumab
  • SBA16: Weekly Fluorouracil/Leucovorin
  • SBA32: Capecitabine + Bevacizumab
  • SBA33: Roswell Park Fluorouracil/Leucovorin + Bevacizumab
  • SBA34: Simplified Biweekly Infusional Fluorouracil/Leucovorin + Bevacizumab
  • SBA35: Weekly Fluorouracil/Leucovorin + Bevacizumab
• Emetic Risk has been updated on the following templates:
  • SBA33: Roswell Park Fluorouracil/Leucovorin + Bevacizumab
  • SBA35: Weekly Fluorouracil/Leucovorin + Bevacizumab
• Changes to the Chemotherapy Regimen section have been made on the following templates:
  • SBA1: mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin)
  • SBA7: CapeOX (Capecitabine/OXALIplatin)
  • SBA9: mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) + Bevacizumab
  • SBA10: CapeOX (Capecitabine/OXALIplatin) + Bevacizumab
  • SBA13: FOLFOXIRI (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin/Irinotecan) + Bevacizumab
  • SBA20: Pembrolizumab
  • SBA21: Nivolumab
  • SBA22: Nivolumab + Ipilimumab followed by Nivolumab
  • SBA23: Albumin-bound PACLitaxel
  • SBA27: DOCEtaxel/Gemcitabine
  • SBA30: GTX (Gemcitabine Fixed-Dose Rate/ DOCEtaxel/Capecitabine)
  • SBA31: Larotrectinib
  • SBA32: Capecitabine + Bevacizumab
  • SBA33: Roswell Park Fluorouracil/Leucovorin + Bevacizumab
  • SBA34: Simplified Biweekly Infusional Fluorouracil/Leucovorin + Bevacizumab
  • SBA35: Weekly Fluorouracil/Leucovorin + Bevacizumab
• Drug information notes for the following agents have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
  • Albumin-bound PACLitaxel
  • Bevacizumab
  • DOCEtaxel
  • Fluorouracil
  • Larotrectinib
  • PACLitaxel

NCCN has published updates to the NCCN Templates for Non-Small Cell Lung Cancer to reflect the currently published NCCN Guidelines for Non-Small Cell Lung Cancer v4.2021.

• Changes to the Indication section have been made on the following NCCN Templates:
  • NSC76: Pembrolizumab + PEMEtrexed/CARBOplatin
  • NSC84: Pembrolizumab + PEMEtrexed/CISplatin
  • NSC85a: Atezolizumab and Bevacizumab + PACLitaxel/CARBOplatin followed by Atezolizumab and Bevacizumab Maintenance - Atezolizumab and Bevacizumab + PACLitaxel/CARBOplatin Course
  • NSC86: Pembrolizumab + PACLitaxel/CARBOplatin followed by Pembrolizumab Maintenance
  • NSC88: Pembrolizumab + Albumin-bound PACLitaxel/CARBOplatin followed by Pembrolizumab Maintenance
  • NSC97: Nivolumab + Ipilimumab
  • NSC98: Atezolizumab + Albumin-bound PACLitaxel/CARBOplatin followed by Atezolizumab Maintenance
  • NSC104: Nivolumab + Ipilimumab + PEMEtrexed/CARBOplatin
  • NSC105: Nivolumab + Ipilimumab + PEMEtrexed/CISplatin
  • NSC106: Nivolumab + Ipilimumab + PACLitaxel/CARBOplatin

NCCN has published an update to the NCCN Templates for Bladder Cancer to reflect the NCCN Guidelines for Bladder Cancer v3.2020.

• The cycle definition has been updated in the Chemotherapy Regimen Section for the following template:
  • BLA1: CISplatin/PACLitaxel with Concurrent Radiation

NCCN has published updates to the NCCN Templates for B-cell Lymphomas to reflect the currently published NCCN Guidelines for B-Cell Lymphomas v3.2021.

For Non-Gastric MALT Lymphoma:

• References have been updated for the following templates:
  • NGMALT15: Copanlisib
• Changes to the Indication section have been made on the following templates:
  • NGMALT5: RiTUXimab
  • NGMALT17: Ibrutinib
• Changes to the Chemotherapy Regimen section have been made on the following templates:
  • NGMALT3: Chlorambucil + RiTUXimab
  • NGMALT7: Chlorambucil
• Drug information notes for the following agents have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
  • Cyclophosphamide

For Splenic Marginal Zone Lymphoma:

• Changes to the Indications section have been made on the following template:
  • SPLN5: RiTUXimab
• Changes to the Indications section have been made on the following template:
  • SPLN13: Copanlisib
• Changes to the Chemotherapy Regimen section have been made on the following templates:
  • SPLN7: Chlorambucil

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Please note: The NCCN Third Party Content FTP site: ftp://ftp1.nccn.org/ThirdPartyContent/ has been updated. Licensees are solely responsible for obtaining permission from such third party to use any such Third Party Content in the Permitted Works.

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.